These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31241371)

  • 1. Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer.
    Sugarman R; Patel R; Sharma S; Plenker D; Tuveson D; Saif MW
    Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):541-552. PubMed ID: 31241371
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
    Garcia G; Odaimi M
    J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of treatments for pancreatic cancer.
    El Hassouni B; Li Petri G; Liu DSK; Cascioferro S; Parrino B; Hassan W; Diana P; Ali A; Frampton AE; Giovannetti E
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):437-447. PubMed ID: 31100206
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ; Chang JY; Shan YS; Chen LT
    Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
    Diab M; Azmi A; Mohammad R; Philip PA
    Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters.
    Deyme L; Barbolosi D; Gattacceca F
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):27-42. PubMed ID: 30446786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic Neoplasms and Autophagy.
    Barton LA; Ren J
    Curr Drug Targets; 2018; 19(9):1018-1023. PubMed ID: 27358060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
    Caparello C; Meijer LL; Garajova I; Falcone A; Le Large TY; Funel N; Kazemier G; Peters GJ; Vasile E; Giovannetti E
    World J Gastroenterol; 2016 Aug; 22(31):6987-7005. PubMed ID: 27610011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
    Cinar P; Ko AH
    Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second line treatment options for pancreatic cancer.
    Passero FC; Saif MW
    Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
    Liu GF; Li GJ; Zhao H
    J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer.
    Sullivan KM; Kozuch PS
    Cancer J; 2012; 18(6):633-41. PubMed ID: 23187852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism.
    Capula M; Mantini G; Funel N; Giovannetti E
    Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1081-1090. PubMed ID: 31721608
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging protein kinase inhibitors for treating pancreatic cancer.
    Furuse J; Nagashima F
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):77-86. PubMed ID: 28253828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for pancreatic cancer.
    Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
    Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.